Adobe sells subscriptions to the tools creative and document workers already use, and the market keeps asking whether generative AI erodes or extends that. Start with the stock courses for method.
The Seat Is the Moat
Adobe sells subscription software to people who make pixels and PDFs, and to marketers who run campaigns. Creative Cloud is the gravity. Document Cloud is the quiet annuity. Experience Cloud is the enterprise argument. Firefly and generative credits are attach. If you cannot say which you are trading, you will treat a Firefly demo as ARR.
Size ADBE as a large-cap SaaS name with competitive and multiple-gap risk. Not a second Microsoft, not a crushed deal souvenir.
1. From PostScript to Creative Cloud
PostScript and desktop publishing created the creative default. The 2013 Creative Cloud conversion turned a boxed-software cycle into a subscription. That conversion is why the multiple exists. The Figma acquisition’s collapse under antitrust (2023) is why the multiple also has a scar: Adobe cannot always buy the next interface.
Generative tools (Firefly) are both defense against Midjourney-class substitution and a new SKU. Defense can work. Defense can also train customers to expect creation without a $50 seat. Watch net-new ARR and credit consumption, not the Super Bowl ad.
PDF and Acrobat are unsexy switching costs in enterprises and governments. Unsexy is good. Unsexy is also where open-source and browser-native tools nibble. Nibbles show up in net-new, not in brand surveys.
2. What the modern company sells
Digital Media (Creative + Document) versus Digital Experience. Subscription ARR, remaining performance, and net-new ARR. A mix shift into Experience can look like growth with a different sales cost. Read sales-and-marketing with the growth.
Customer is prosumers, agencies, enterprises. A seat that is a hobbyist is more elastic than a seat that is a newsroom. Price hikes land differently. Do not average them.
Competition is Figma (still independent), Canva-class, Microsoft, and generative startups. The blocked deal did not remove Figma. It left it alive on purpose. Seat-based like Salesforce, but Adobe's seats sit with creators and document workers rather than sales teams, so the AI risk shows up in different places.
3. Why it still compounds — and what stops it
Default formats (PSD, PDF, Premiere) and muscle memory are the moat. Slower net new ARR in the same quarter that AI image tools dominate the headlines can still cut the multiple sharply.
What stops compounding: a durable net-new stall, a generative substitution that actually cuts seats, or an Experience miss that reveals Digital Media as ex-growth.
ADBE can print huge FCF and still be a poor long if you paid for a growth rate the seats no longer earn.
4. How traders actually use the ticker
ADBE gaps on ARR and on AI-competition headlines. Beta is higher than the “quality software” label. Size for the print. Earnings reactions in ADBE have been large on guidance tone, so let the risk calculator set size from the stop rather than the logo. A spike on the stock scanner near a print is usually guidance, not news about a product.
As an illustration, $60,000 with $600 at risk and $18 from a $355 entry to the stop comes to about 33 shares. Put that in the written trading plan ahead of the report, and go back to the risk rules if you cannot say where the idea is wrong.
Pairs vs MSFT only with a relative creative-or-document view. Otherwise you doubled software duration.
5. Mistakes, limits, takeaways
Mistakes: Firefly-as-ARR; ignoring Figma as a live competitor; treating PDF as immortal without checking net-new. Annualised recurring revenue and Digital Media net new ARR are the lines to track in filings; the statements course explains the statements; if you are new to shares, start with What Is Stock Trading?.
What matters most
- Net-new ARR is the scoreboard.
- Firefly counts as attach until it bills.
- Figma is still a competitor.
- Size for an ARR miss.
Adobe's moat is workflow habit, and the stock trades on whether people think that habit survives AI tools. Educational only. Not tax, legal, or a recommendation to buy, sell, or hold ADBE.